Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART
NCT03706950
·
clinicaltrials.gov ↗
UNKNOWN
Status
2000
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV-1-infection
Interventions
DRUG:
Elpida® + 2 NRTIs
Sponsor
Viriom